Kyung-Hun Lee

Ewha Womans University — South Korea

Medicine · Health Sciences

43h-index10.5kcitations424works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(70), HER2/EGFR in Cancer Research(67), PARP inhibition in cancer therapy(54), Breast Cancer Treatment Studies(49), Colorectal Cancer Treatments and Studies(41)

Publications424 total

Data from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figures S1-11 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Table S1 and S4 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Longitudinal trajectory of menopausal symptoms in premenopausal women throughout adjuvant chemotherapy: a two-stage analytical approach
Supportive Care in Cancer·2025
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
ESMO Open·2025Open Access
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Clinical Cancer Research·2025· 1 cited
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
BMC Cancer·2025Open Access
Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer
Cancer Cell International·2025Open Access
MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer
Breast Cancer Research·2025· 2 citedOpen Access
Factors Associated with Continuous Loss to Follow-up in Cancer Patients
Quality Improvement in Health Care·2025Open Access
Abstract PS17-10: Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21)
Clinical Cancer Research·2025
Abstract P3-11-05: Three-year efficacy and safety of neoadjuvant chemotherapy with pertuzumab, atezolizumab, docetaxel, and trastuzumab in patients with stage II/III ERBB2-positive breast cancer (NeoPATH): a nonrandomized, multi-institutional, phase 2 trial
Clinical Cancer Research·2025
Abstract PS12-01: Olaparib-induced early dynamics of tumor immune microenvironment in triple-negative or ER-low breast cancer: insights from a window of opportunity MEDIOLA trial of olaparib and durvalumab with serial biopsies
Clinical Cancer Research·2025
Abstract P4-07-19: Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial
Clinical Cancer Research·2025
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
Journal of Clinical Oncology·2025· 2 cited
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13).
Journal of Clinical Oncology·2025· 1 cited
Use of artificial intelligence (AI)–powered spatial analysis to predict pathologic complete response (pCR) in HR+ HER2- breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC).
Journal of Clinical Oncology·2025
Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models
Breast Cancer Research·2025· 2 citedOpen Access
page 1 of 22Next →

Frequent Co-authors

Seock‐Ah Im(37), Do‐Youn Oh(21), Sae‐Won Han(19), Yung‐Jue Bang(19), Tae‐Yong Kim(17), Tae‐You Kim(13), Wonshik Han(9), Dae‐Won Lee(8), Jee Hyun Kim(5), Yeon Hee Park(5), Tae Yong Kim(5), Dong‐Young Noh(5), Dae Seog Heo(4), In Ae Park(4), Winnie Yeo(4), Seung‐Yong Jeong(4), Gyeong Hoon Kang(4), Koung Jin Suh(4), Han Suk Ryu(4), Hyeong‐Gon Moon(4)